DailyIQ
|
Sector:HealthcareAll sectors
Last updated 24 minutes ago

ROIV·ROIV

$.
-. (-.%)
After Hours
High
$26.92
Open
$26.50
Market Cap
18.93B
52W High
$27.94
Low
$26.15
P. Close
$28.21
P/E
-
52W Low
$8.73
Fwd P/E
-
Mean Target
-
Technical Score (1D)
95
BUY
News Sentiment
65
BULLISH
Citi and H.C. Wainwright have increased their price targets for Roivant Sciences (ROIV) to $35 and $33, respectively, following positive Phase 2 data for brepocitinib in cutaneous sarcoidosis. This development reflects growing analyst optimism regarding ROIV's pipeline and the potential for brepocitinib's growth. The analysts are incorporating revenue projections into their financial models, suggesting a belief in the drug's commercial viability. Bank of America also adjusted its price target, though it maintained a Neutral rating. The market will be watching for further updates on brepocitinib's clinical trials and potential regulatory filings.
Earnings Summary
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company within the healthcare sector, specifically the biotechnology industry, focused on discovering, developing, and commercializing medicines and technologies. The company's clinical product candidates include treatments for various diseases. In Q1 2025, Roivant Sciences reported an EPS of -0.21829 against an estimate of -0.16333, with revenues of $7,570,000. In the subsequent quarter, Q1 2026, the company's EPS and revenue figures are not available. The company's recent performance shows an EPS miss in Q1 2025, with revenue data available for only one of the two most recent quarters. Not enough information is available to analyze EPS and revenue growth trends. The company's financial performance shows a mixed picture, with an EPS miss in the most recent quarter and limited revenue data available for comparison. Recent news indicates positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, leading to upgrades from analysts and positive share price momentum. The company also reported an NDA submission for brepocitinib in dermatomyositis. Investors should watch for further developments in the brepocitinib pipeline and the release of topline data from Phase 3 studies in the second half of 2026, as well as the progress of other pipeline projects.

EPS

EstBeatMiss
$-0.34$-0.29$-0.24$-0.19$-0.14Q1'25Q1'26
QtrEstActual+/−
Q1'26$-0.31 - -
Q1'25$-0.16$-0.22-33.6%

Revenue

EstBeatMiss
$4M$5M$6M$7M$8MQ1'25Q1'26
QtrEstActual+/−
Q1'26$4M - -
Q1'25 - $8M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ROIV Stock Snapshot

ROIV is currently trading at $32.14, giving ROIV a market cap of 18.93B. Today's range spans $26.15–$26.92, with shares opening at $26.50 and moving up $3.93 (13.9%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 65/100.

Over the past year ROIV has traded between $8.73 and $27.94 - the current price is +268.2% off the 52-week low and +15.0% from the high.

The combination of bullish technicals and bullish sentiment for ROIV (ROIV) is the kind of setup that shows up in systematic screens before the more discretionary investors arrive. Score 95/100 (BUY), price $32.14 (near 52-week highs), sentiment 65/100. At 18.93B in Healthcare market cap, this large-cap name has the right size to matter to a wide range of buyers. Annual range: $8.73–$27.94.

The combination of a BUY signal (95/100) and bullish news sentiment (65/100) puts ROIV on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 18.93B in Healthcare market cap without immediately moving the stock. At $32.14 (near 52-week highs in the $8.73–$27.94 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…